CRISPR Therapeutics

CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak.[6] Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases.[7] The current CEO of the company is Samarth Kulkarni, PhD, who joined the company in 2015 as Chief Business Officer. Kulkarni became CEO in 2017.

CRISPR Therapeutics has formed various collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease.[8] One of the first potential treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex have expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes.[9][10] In 2016, the company signed an agreement with Bayer AG, and started to operate Casebia Therapeutics as a joint venture with Bayer, which is now operated under the management of CRISPR Therapeutics.[11] The company went public on the NASDAQ exchange in October of 2016.[12]

CRISPR Therapeutics has established partnerships with a number of additional companies such as Viacyte (now part of Vertex), Nkarta, Capsida, Curevac, and others.[13][14][15]

CRISPR Therapeutics has several drugs in development for blood diseases, cancer, diabetes, and other severe diseases. These include the drug exa-cel for the treatment of the rare blood disorders Beta thalassemia and sickle cell disease, which is being developed jointly with Vertex Pharmaceuticals.[7] In May 2020, exa-cel received Orphan drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia.[16] Phase 3 clinical trial results support the safety and efficacy of this treatment.[17][18][19][20] The rolling Biologics License Applications (BLAs) were submitted to the U.S. Food and Drug Administration (FDA) for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. Additionally, EU and UK filings were completed in 2022, and these submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency.[21]

• Editas Medicine
• Intellia Therapeutics